Stocktoria
Outlook Therapeutics, Inc. OTLK
Outlook Therapeutics, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — | — | $8.1M | $3.1M | — | $3.8M |
| Gross profit | $57,205 | — | — | — | — | — | — | — | — | — |
| R&D expense | $27.2M | $41.8M | $26.5M | $42.3M | $39.0M | $26.3M | $23.8M | $18.5M | — | $23.8M |
| SG&A expense | $39.9M | $29.9M | — | — | — | — | — | — | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M | -$36.8M | -$36.3M | -$29.6M | — | -$35.9M |
| Interest expense | — | — | — | — | — | $1.8M | $3.5M | $3.9M | — | $5.6M |
| Income tax | -$1.6M | $2,800 | $2,800 | $2,800 | $2,000 | -$3.3M | -$3.4M | -$3.6M | $3.1M | $501,500 |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M | -$35.2M | -$34.5M | -$30.1M | — | -$38.8M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.72 | $-0.31 | $-0.35 | $-0.67 | — | $-1.22 | — | $-1.80 |
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M | -$31.8M | -$32.3M | -$33.0M | — | -$15.5M |
| Free cash flow | — | — | — | — | — | — | -$32.7M | -$35.8M | — | -$15.8M |
| Cash & equivalents | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M | $12.5M | $8.0M | $1.7M | $13.8M | $3.2M |
| Inventory | $3.3M | — | — | — | — | — | — | — | — | — |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M | $19.7M | $17.1M | $22.3M | $32.3M | $20.7M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M | $16.9M | $27.9M | $43.1M | $40.2M | $51.5M |
| Shareholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.7M | $4.6M | $2.8M | -$16.1M | -$25.5M | -$25.1M | -$33.7M |
Growth · year-over-year · Revenue CAGR -28.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | +163.8% | — | — | +27.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.